Mauro Gori1, Michele Senni2, Deepak K Gupta1, David M Charytan3, Elisabeth Kraigher-Krainer4, Burkert Pieske4, Brian Claggett1, Amil M Shah1, Angela B S Santos1, Michael R Zile5, Adriaan A Voors6, John J V McMurray7, Milton Packer8, Toni Bransford9, Martin Lefkowitz9, Scott D Solomon10. 1. Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis St, Boston 02445, MA, USA. 2. Cardiovascular Department, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy. 3. Renal Division and Clinical Biometrics, Brigham and Women's Hospital, Boston, MA, USA. 4. Medical University Graz, Graz, Austria. 5. Medical University of South Carolina, Charleston, SC, USA U.S. Department of Veterans Affairs, Ralph H. Johnson VA Medical Center, Charleston, SC, USA. 6. University of Groningen, Groningen, The Netherlands. 7. University of Glasgow, Glasgow, UK. 8. University of Texas Southwestern, Dallas, TX, USA. 9. Novartis Pharmaceuticals, East Hanover, NJ, USA. 10. Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis St, Boston 02445, MA, USA ssolomon@rics.bwh.harvard.edu.
Abstract
AIM: Renal dysfunction is a common comorbidity in patients with heart failure and preserved ejection fraction (HFpEF). We sought to determine whether renal dysfunction was associated with measures of cardiovascular structure/function in patients with HFpEF. METHODS: We studied 217 participants from the PARAMOUNT study with HFpEF who had echocardiography and measures of kidney function. We evaluated the relationships between renal dysfunction [estimated glomerular filtration rate (eGFR) >30 and <60 mL/min/1.73 m(2) and/or albuminuria] and cardiovascular structure/function. RESULTS:The mean age of the study population was 71 years, 55% were women, 94% hypertensive, and 40% diabetic. Impairment of at least one parameter of kidney function was present in 62% of patients (16% only albuminuria, 23% only low eGFR, 23% both). Renal dysfunction was associated with abnormal LV geometry (defined as concentric hypertrophy, or eccentric hypertrophy, or concentric remodelling) (adjusted P = 0.048), lower midwall fractional shortening (MWFS) (P = 0.009), and higher NT-proBNP (P = 0.006). Compared with patients without renal dysfunction, those with low eGFR and no albuminuria had a higher prevalence of abnormal LV geometry (P = 0.032) and lower MWFS (P < 0.01), as opposed to those with only albuminuria. Conversely, albuminuria alone was associated with greater LV dimensions (P < 0.05). Patients with combined renal impairment had mixed abnormalities (higher LV wall thicknesses, NT-proBNP; lower MWFS). CONCLUSION:Renal dysfunction, as determined by both eGFR and albuminuria, is highly prevalent in HFpEF, and associated with cardiac remodelling and subtle systolic dysfunction. The observed differences in cardiac structure/function between each type of renal damage suggest that both parameters of kidney function might play a distinct role in HFpEF. Published on behalf of the European Society of Cardiology. All rights reserved.
RCT Entities:
AIM: Renal dysfunction is a common comorbidity in patients with heart failure and preserved ejection fraction (HFpEF). We sought to determine whether renal dysfunction was associated with measures of cardiovascular structure/function in patients with HFpEF. METHODS: We studied 217 participants from the PARAMOUNT study with HFpEF who had echocardiography and measures of kidney function. We evaluated the relationships between renal dysfunction [estimated glomerular filtration rate (eGFR) >30 and <60 mL/min/1.73 m(2) and/or albuminuria] and cardiovascular structure/function. RESULTS: The mean age of the study population was 71 years, 55% were women, 94% hypertensive, and 40% diabetic. Impairment of at least one parameter of kidney function was present in 62% of patients (16% only albuminuria, 23% only low eGFR, 23% both). Renal dysfunction was associated with abnormal LV geometry (defined as concentric hypertrophy, or eccentric hypertrophy, or concentric remodelling) (adjusted P = 0.048), lower midwall fractional shortening (MWFS) (P = 0.009), and higher NT-proBNP (P = 0.006). Compared with patients without renal dysfunction, those with low eGFR and no albuminuria had a higher prevalence of abnormal LV geometry (P = 0.032) and lower MWFS (P < 0.01), as opposed to those with only albuminuria. Conversely, albuminuria alone was associated with greater LV dimensions (P < 0.05). Patients with combined renal impairment had mixed abnormalities (higher LV wall thicknesses, NT-proBNP; lower MWFS). CONCLUSION:Renal dysfunction, as determined by both eGFR and albuminuria, is highly prevalent in HFpEF, and associated with cardiac remodelling and subtle systolic dysfunction. The observed differences in cardiac structure/function between each type of renal damage suggest that both parameters of kidney function might play a distinct role in HFpEF. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Michael R Zile; John S Gottdiener; Scott J Hetzel; John J McMurray; Michel Komajda; Robert McKelvie; Catalin F Baicu; Barry M Massie; Peter E Carson Journal: Circulation Date: 2011-11-07 Impact factor: 29.690
Authors: Frank P Brouwers; Rudolf A de Boer; Pim van der Harst; Adriaan A Voors; Ron T Gansevoort; Stephan J Bakker; Hans L Hillege; Dirk J van Veldhuisen; Wiek H van Gilst Journal: Eur Heart J Date: 2013-03-06 Impact factor: 29.983
Authors: Joachim H Ix; Michael G Shlipak; Glenn M Chertow; Sadia Ali; Nelson B Schiller; Mary A Whooley Journal: J Card Fail Date: 2006-10 Impact factor: 5.712
Authors: Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Ali Ahmed; Michael W Rich; Paul W Sanders; Gilbert J Perry; George L Bakris; Michael R Zile; Thomas E Love; Inmaculada B Aban; Michael G Shlipak Journal: Am J Cardiol Date: 2006-12-08 Impact factor: 2.778
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Scott D Solomon; Julie Lin; Caren G Solomon; Kathleen A Jablonski; Madeline Murguia Rice; Michael Steffes; Michael Domanski; Judith Hsia; Bernard J Gersh; J Malcolm O Arnold; Jean Rouleau; Eugene Braunwald; Marc A Pfeffer Journal: Circulation Date: 2007-11-19 Impact factor: 29.690
Authors: Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: Senthil Selvaraj; Brian Claggett; Sanjiv J Shah; Inder Anand; Jean L Rouleau; Eileen O'Meara; Akshay S Desai; Eldrin F Lewis; Bertram Pitt; Nancy K Sweitzer; James C Fang; Marc A Pfeffer; Scott D Solomon Journal: Circ Heart Fail Date: 2018-11 Impact factor: 8.790
Authors: Ravi B Patel; Rupal Mehta; Margaret M Redfield; Barry A Borlaug; Adrian F Hernandez; Sanjiv J Shah; Ruth F Dubin Journal: J Card Fail Date: 2020-01-11 Impact factor: 5.712
Authors: Baris Afsar; Patrick Rossignol; Loek van Heerebeek; Walter J Paulus; Kevin Damman; Stephane Heymans; Vanessa van Empel; Alan Sag; Alan Maisel; Mehmet Kanbay Journal: Heart Fail Rev Date: 2017-11 Impact factor: 4.214
Authors: Daisuke Kamimura; Takeki Suzuki; Anna L Furniss; Michael E Griswold; Iftikhar J Kullo; Merry L Lindsey; Michael D Winniford; Kenneth R Butler; Thomas H Mosley; Michael E Hall Journal: J Cardiovasc Med (Hagerstown) Date: 2017-12 Impact factor: 2.160
Authors: Keyvan Yousefi; Camila I Irion; Lauro M Takeuchi; Wen Ding; Guerline Lambert; Trevor Eisenberg; Sarah Sukkar; Henk L Granzier; Mei Methawasin; Dong I Lee; Virginia S Hahn; David A Kass; Konstantinos E Hatzistergos; Joshua M Hare; Keith A Webster; Lina A Shehadeh Journal: J Am Coll Cardiol Date: 2019-06-04 Impact factor: 24.094